With Merck’s COVID Antiviral Announcement, Can the Pharma Pipeline Build Treatment Momentum?

 

At the start of the month, pharmaceutical company Merck dropped big news: It has developed a COVID antiviral drug that would cut hospitalization and mortality risks by 50%. In the drug’s study, patients taking the placebo pill saw 14% hospitalization rate and eight deaths, while the trial group with Merck’s drug had only 7% hospitalized and zero deaths.

This appears to be just the tip of the iceberg; Kaiser Health News reports at least three COVID antiviral candidates, including Merck’s, going through late-stage clinical trials, meaning a variety of COVID drugs could be on patient’s prescriptions here soon. What’ll be some of the positive domino effects to come from approval of COVID antivirals, not only on the pharmaceutical production pipeline, but on the general population’s health? Ira Leiderman, managing director of the healthcare practice at Cassel Salpeter & Co., gave MarketScale his take on the coming treatments.

Follow us on social media for the latest updates in B2B!

Image

Latest

promoted
How to Succeed After Getting Promoted: Seeking Feedback, Acting with Intention, and Leading with Perspective
April 16, 2026

Stepping into a leadership role today isn’t just a step up—it’s a shift into constant visibility, where expectations arrive immediately and the margin for error narrows. As organizations flatten structures and demand faster decisions, newly promoted leaders are expected to deliver impact from the outset, often without the space to fully adjust. According to…

Read More
AI in business
A Practical Conversation About AI in Business: From Hype to Real-World Impact
April 15, 2026

Artificial intelligence has moved from buzzword to boardroom priority at a staggering pace. Yet despite widespread adoption, many organizations are still struggling to turn experimentation into measurable business value—some estimates suggest the majority of enterprise AI initiatives fail to scale successfully. As AI becomes “table stakes” across industries, the real challenge is no longer…

Read More
weekly drive-in
Metropolis: Weekly Drive-in
April 15, 2026

Metropolis “Weekly Drive In” reflects a new era of storytelling where AI meets real-world execution, turning everyday field performance into momentum. Centered on genuine conversions and local wins, the series highlights how the company is scaling not just through technology, but through visibility and shared recognition. In an emerging recognition economy, these updates act…

Read More
Drive In, Drive Out: The Rhythm of Metropolis
April 15, 2026

Behind the seemingly mundane choreography of a drive-in lies a broader story about how modern cities script behavior, turning even the simplest actions into rehearsed routines. What looks like repetition is really a quiet testament to systems designed for flow and control, where efficiency often outweighs individuality. In places like Metropolis, the rhythm of…

Read More